Safety Data Sheet
European Format

Methotrexate Sodium Tablets

Preparation Date 08-Jan-2007 **Revision Date** 31-Mar-2008 **Revision Number** 2

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Name Methotrexate Sodium Tablets
Common Name Not available
Chemical Name Not applicable
Synonyms Rheumatrex, Methotrexate
Product Use Pharmaceutical product
Classification Antineoplastic Agent - Cytostatic

Supplier
Wyeth
P.O. Box 8299
Philadelphia, PA 19101 USA.
Telephone: 1-610-688-4400

Emergency Telephone Number
Chemtrec USA, Puerto Rico, Canada 1-800-424-9300
Chemtrec International 1-703-527-3887

2. COMPOSITION/INFORMATION ON INGREDIENTS

Common Name	CAS-No	EC No.	Composition	Classification
Methotrexate	59-05-2	2004138	2.5 - 10 mg/tablet	T, Xi; R23/24/25, 40, 46, 61; S45, 53

3. HAZARDS IDENTIFICATION

Emergency Overview
This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

Appearance Pharmaceutical Tablet or Capsule **Physical State** Solid **Odor** Not available

Potential Physical Hazards
Powders and solids are presumed to be combustible.

Potential Health Effects

Eyes Irritating to eyes.
Skin Irritating to skin.
Inhalation Irritating to respiratory system.
Ingestion The most common effects may include bone marrow depression, hepatotoxicity, pulmonary toxicity, cutaneous and sensitivity reactions, mouth ulceration, nausea, vomiting, diarrhea, central nervous system effects, back pain, blurred vision, confusion, dizziness, drowsiness, fever, headache, and unusual tiredness or weakness.

May cause harm to the unborn child. May cause harm to breastfed babies. May cause inheritable genetic damage.

Please see Patient Package Insert for further information.

Therapeutic Target Organ(s)	Systemic.
	Not listed by OSHA, NTP or IARC.
Potential Environmental Effects	There is no known ecological information for this product.

4. FIRST AID MEASURES

Eye Contact	In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.
Skin Contact	Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
Inhalation	Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.
Ingestion	If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties	Not flammable
Extinguishing Media	
Suitable Extinguishing Media	Use water spray, foam, dry chemical or carbon dioxide.
Unsuitable Extinguishing Media	Do NOT use water jet.
Fire Fighting	Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.
Hazardous Combustion Products	Carbon oxides, nitrogen oxides.
Protective Equipment and Precautions for Firefighters	In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions	Refer to protective measures listed in Sections 7 and 8.
Environmental Precautions	Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.
Methods for Containment	Not available
Methods for Cleaning up	Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

7. HANDLING AND STORAGE

Handling	For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.
Storage	No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common Name	**Exposure Guideline**
Methotrexate	0.1 mcg/m^3

Engineering Controls Enclose operations to prevent aerosol generation. Use HEPA filtered, externally vented, biosafety cabinet when preparing or handling this product.

Personal Protective Equipment

Eye/face Protection Wear safety glasses with side-shields.

Skin Protection Wear double gloves or "chemotherapy" gloves. Immediately change gloves when torn, punctured, or contaminated. Wear closed-front, low-permeability protective gowns with tight-fitting wrist cuffs when working with this product.

Respiratory Protection Base respirator selection on a risk assessment.

General Hygiene Considerations Avoid contact with skin, eyes and clothing. Conduct a task-specifc risk assessment prior to authorizing work with this product. Wash hands and face before breaks and immediately after handling the product.

Other Limit access to only personnel trained in the safe handling of this material. Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	Pharmaceutical Tablet or Capsule	**Physical State**	Solid
Color	Various	**Odor**	Not available
Odor Threshold	Not available		
pH	Not applicable		
Specific Gravity	Not applicable	**Water Solubility**	Insoluble in water
Solubility	Not applicable	**Evaporation Rate**	Not applicable
Partition Coefficient (n-octanol/water)	Not available	**Vapor Density**	Not applicable
Vapor Pressure	Not applicable		
Boiling Point	Not applicable	**Autoignition Temperature**	Not applicable
Flash Point	Not applicable	**Method**	None
Melting Point	Not available		
Flammability Limits in Air	**Upper** Not applicable	**Lower** Not applicable	
Explosion Limits	**Upper** Not applicable	**Lower** Not applicable	

10. STABILITY AND REACTIVITY

Chemical Stability Stable at room temperature.

Conditions to Avoid No data available

Materials to Avoid No materials to be especially mentioned.

Hazardous Decomposition Products None under normal use.

Possibility of Hazardous Reactions None under normal use.

11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Acute Toxicity

Methotrexate

LD50 Oral	180 - 317 mg/kg rats >2000 mg/kg rabbits
Acute Dermal Irritation	Not applicable
Primary Eye Irritation	Not applicable
Sensitization	Not applicable

Multiple Dose Toxicity

Methotrexate

No Toxicologic Effect Dose/Species/Study Length:	Methotrexate toxicity in animals was characterized by gastrointestinal hemorrhage, weakness, emesis, diarrhea, weight loss, bone marrow suppression, and liver damage.

Maximum Tolerated Dose (MTD), Oral

Methotrexate

Carcinogenicity	Carcinogenicity studies in rats have been inconclusive. Signs of toxicity were related to characteristic bone marrow suppression and liver damage. The IARC group has evaluated Methotrexate for its carcinogenic potential and found inadequate evidence for Carcinogenicity in either humans or animals (Group 3).
Genetic Toxicity	AMES Test :Negative- Nonmutagenic Weakly positive in the mouse lymphoma assay, and positive in the cell transformation assay. It also induced chromosomal aberrations and increased the incidence of sister chromatid exchange. In vivo, it increased the incidences of polychromatic erythrocytes and chromosomal aberrations.
Reproductive Toxicity	No data available
Developmental Toxicity	Methotrexate induced teratogenic effects and embryolethality in several species, including humans, at doses that are non-toxic to the mother.

Methotrexate

Target Organ(s) of Toxicity	No data available

12. ECOLOGICAL INFORMATION

Chemical Fate Information Not available

Ecotoxicity Not available

13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

15. REGULATORY INFORMATION

According to present data no classification and labeling is required according to Directives 67/548/EEC or 1999/45/EC.

16. OTHER INFORMATION

Prepared By	Wyeth Department of Environment, Health & Safety
Format	This MSDS was prepared in accordance with Directive 2001/58/EC.
List of References	Product Profiles
Revision Summary	Change to OEG.

Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS